Review Note
Last Update: 01/24/2025 08:27 AM
Current Deck: Geneeskunde::3e bachelor::Nier en spijs::ZSO 32: Nierfarmacologie::Shanna's Snelweg naar Succes
New Card (Unpublished)Currently Published Content
Question
Title
QType (0=kprim,1=mc,2=sc)
Q_1
Q_2
Q_3
Q_4
Q_5
Answers
Sources
Extra 1
No published tags.
Pending Suggestions
Field Change Suggestions:
Question
Commit #268356
Although the patient's disease was adequately controlled with
an NSAID and rnethotrexate for some time, her symptoms
began to worsen and radiologic studies of her hands indicated
progressive destruction in the joints of several fingers. Treat
ment with another second-line agent for rheumatoid arthri
tis was considered. Which of the following is a parenterally
administered DMARD whose mechanism of anti-inflamma
tory action is antagonism of tumor necrosis factor?
Title
Commit #268356
A 54-year-old woman presented with signs
and symptoms consistent with an early stage of rheumatoid arthri
tis. The decision was made to initiate NSAID therapy.
QType (0=kprim,1=mc,2=sc)
Commit #268356
2
Q_1
Commit #268356
(A) Anakinra
Q_2
Commit #268356
(B) Abatacept
Q_3
Commit #268356
(C) Etanercept
Q_4
Commit #268356
(D) Penicillamine
Q_5
Commit #268356
(E) Sulfasalazine
Answers
Commit #268356
0 0 1 0 0
Sources
Commit #268356
Katzung
Extra 1
Commit #268356
Etanercept is a recombinant protein that binds to tumor
necrosis factor and prevents its inflammatory effects.
The answer is C.